

**REMARKS**

Claims 1-5, 7-9, 14 and 20 have been canceled. Claims 13 and 15-19 are active in the case.

The present invention relates to amide compounds that are useful in the treatment of amnesia or dementia.

**Claim Rejection, 35 USC 112, First Paragraph**

The basis for the new matter rejection is not understood since ample basis can be found for the definitions of groups  $R^1$ , Y, Q and  $R^2$  in the text of the specification.

As to the definition of  $R^1$  as acyl in Claim 13, such is clearly stated at page 2, line 26 of the text, as well as at page 14, lines 29-32. Further regarding the definition of  $R^1$  in each of Claims 13 and 16, support for the insertion of the term lower alkoxy carbonyl into the definition of the group can be found at page 14, line 30 of the specification. This amendment represents the only expansion in a definition of a group in the active claims.

Basis for the definition of  $R^1$  as set forth in Claim 19 can be found on page 13, lines 18-24. Basis for the recitation of methoxycarbonyl and tert-butoxycarbonyl as lower alkoxy carbonyl, can be found on page 14, line 34 of the specification.

As to group  $R^2$ , the scope of this group has been very substantially reduced in scope, and is now limited to arylamino which is optionally substituted by halogen or pyridylamino. In other words, the limitation of Claim 14 has been placed into Claim 13.

Appl. No. 10/618,743

Reply to the Advisory Action of February 15, 2006

Y has been limited to a single double bond in view of the Examiner's comments in the Advisory Action and Q has been limited to carbonyl (see page 16 of the specification).

Clearly, the present claims do not introduce new matter into the case with respect to the definitions of groups R<sup>1</sup> and R<sup>2</sup>. Accordingly, the new matter rejection of the claims is without merit and withdrawal of the rejection based on 35 USC 112 is respectfully requested.

Having canceled Claims 1-5 and 7-9, the issues set forth in paragraph 3 of the Office Action are believed obviated. Only Claims 13 and 15-19 remain active in the case.

It is believed that the application is in proper condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



Frederick D. Vastine, Ph.D.  
Registration No. 27,013

Customer Number  
**22850**

Tel: 703-413-3000  
Fax: 703-413-2220  
NFO/FDV